1)Gasperini JL, Fawzi AA, Khondkaryan A et al:Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol 96:14-20, 2012
2)Eghøj MS, Sørensen TL:Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol 96:21-23, 2012
3)Patel KH, Chow CC, Rathod R et al:Rapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab. Eye 27:663-667, 2013
4)Bakall B, Folk JC, Boldt HC et al:Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol 156:15-22, 2013
5)Ho VY, Yeh S, Olsen TW et al:Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors. Am J Ophthalmol 156:23-28, 2013
6)Yonekawa Y, Andreoli C, Miller JB et al:Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degene-ration. Am J Ophthalmol 156:29-35, 2013
7)Cho H, Shah CP, Weber M et al:Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab. Br J Ophthalmol 97:1032-1035, 2013
8)Kumar N, Marsiglia M, Mrejen S et al:Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina 33:1605-1612, 2013
9)Miura M, Iwasaki T, Goto H:Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis. Clin Ophthalmol 7:591-595, 2013
10)田野保雄・大路正人・石橋達朗・他:ラニビズマブ治療指針策定委員会:ラニビズマブ(遺伝子組換え)の維持期における再投与ガイドライン.日眼会誌 113:1098-1103,2009
11)髙橋寛二:加齢黄斑変性に対するラニビズマブの実践的投与方法.臨眼 67:1818-1828,2013